UNSPSC 51273829: Methyl salicylate/trolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE650. This VA Drug Class (DE650) classifies this compound as belonging to the group ANALGESICS, TOPICAL.

UNSPSC 51273829 Methyl salicylate/trolamine, a Commodity code, does not map clearly to the state and local procurement activity currently being solicited under it. The three recent opportunities on record—naloxone procurement for Seminole County, Florida; a therapeutic pharmacy initiative RFI from the Texas Health and Human Services Commission; and a multistate cooperative pharmaceutical contract from the Minnesota Department of Administration—address naloxone, generic pharmaceuticals, and OTC products through direct-to-manufacturer and wholesaler channels, but show no meaningful activity in topical salicylate or trolamine compounds. The code's nominal scope (a localized rubefacient / counter-irritant product) diverges sharply from the opioid antagonist and broad-spectrum pharmaceutical procurement dominating current state and local solicitations under this classification.

Recent opportunities originate from health agencies and cooperative purchasing mechanisms across Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a two-year RFP effective July 1, 2026, for generic multi-source pharmaceuticals and OTC products due March 26, 2026, and Seminole County issuing an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Texas RFI (HHS0017013, response deadline April 3, 2026) operates as exploratory market intelligence rather than a binding solicitation. The code shows little relevant recent activity aligned with its stated product definition, suggesting either a data classification mismatch or minimal current procurement demand for methyl salicylate/trolamine formulations in the state and local market.